key: cord-0883781-arkaq3mq
authors: Bittar, João H.J.; Palomares, Roberto A.; Hurley, David J.; Hoyos-Jaramillo, Alejandro; Rodriguez, Adriana; Stoskute, Agne; Hamrick, Brianna; Norton, Natalie; Adkins, Morgan; Saliki, Jeremiah T.; Sanchez, Susan; Lauber, Kelsey
title: Immune response and onset of protection from Bovine viral diarrhea virus 2 infection induced by modified-live virus vaccination concurrent with injectable trace minerals administration in newly received beef calves
date: 2020-04-27
journal: Vet Immunol Immunopathol
DOI: 10.1016/j.vetimm.2020.110055
sha: f17c5ceaf1cfe617fcc028da408d0253df388cb7
doc_id: 883781
cord_uid: arkaq3mq

Abstract Strategies to improve the onset of protective immunity induced by vaccination against respiratory pathogens may have a significant impact on health of newly received beef calves. The objective was to determine if the use of injectable trace minerals (ITM; Se, Zn, Cu, and Mn) concurrent with a modified-live virus (MLV) vaccine enhances the immune response and onset of protection in beef calves challenged with BVDV2 five days after vaccination. Forty-five calves were randomly assigned to one of three groups (15/group): VAC + ITM, received MLV-vaccine and ITM (Multimin®90) subcutaneously (SC); VAC + SAL, received the same vaccine and saline SC; or UNVAC, unvaccinated. Five days after vaccination (d.0), calves were challenged with BVDV2 strain 890. Health status was evaluated and blood samples were collected for leukocyte counts, BVDV1 and 2 serum neutralizing antibody (SNA), BVDV-PCR, percentage of CD4+, CD8+, WC1+ and CD25+ T-cells. VAC + ITM had lower health scores than UNVAC (d.8 and 9). VAC + ITM had higher BVDV1 & 2 SNA titers than VAC + SAL and UNVAC on d.21 and 28. Lymphocyte counts decreased in UNVAC but not in VAC + ITM or VAC + SAL (d.3 to 11). CD4+ T-cells significantly decreased in UNVAC and VAC + SAL (d.3). VAC + ITM had higher percentage of CD4+ cells than UNVAC (d.3 and 7). VAC + ITM had lower percentage of activated CD4+ and CD8+ than UNVAC (d.7). In summary, vaccination induced a rapid protection against BVDV2 infection. Administration of ITM was associated with increased SNA response to BVDV1 & 2, enhanced health status, mitigation of CD4+ T-cells decreased, and reduction of T-cell activation in calves challenged with BVDV2 five days after immunization. These results support the strategic use of ITM concurrent with vaccination, especially when a rapid protection is needed in newly received beef calves.

spread of the virus in the herd, diagnosis and culling of persistently infected animals, allied with vaccination (Brock et al., 2004; Walz et al., 2010) .

Vaccination with attenuated or inactivated vaccines is an efficient tool to prevent and lessen the impact of BVDV infections (Dean and Leyh, 1999; Newcomer et al., 2017) . Despite the commercial availability of several highly efficacious vaccines in the USA, a significant number of producers do not vaccinate their calves against BVDV or other BRD pathogens. The efficacy of vaccination to prevent BVDV infection can be assessed by the vaccine's capacity to induce robust humoral and cell-mediated immune responses able to control virus replication, viremia and shedding (Rhodes et al. 1999; Reber et al., 2006) . Another crucial aspect when assessing the efficacy of BRD vaccines is the rapidity in inducing an adequate immune response to protect cattle against acute infections and disease (Palomares et al., 2012) . This trait is especially important in stockyards and feedlots, where continuous addition of highly stressed cattle with unknown vaccination history and infectious status rises the risk of infections and clinical disease resulting in high morbidity and mortality rates and significant economic losses.

Previous studies characterized the onset of protection induced by modified-live virus (MLV) vaccines administered 7, 5, or 3 days before BVDV challenge with high or low virulence BVDV strains (Brock et al., 2007; Palomares et al., 2012) . In both trials, calves vaccinated 5 and 7 days before BVDV challenge were protected from clinical disease, viremia, leukopenia, and virus shedding compared with unvaccinated calves (Brock et al., 2007; Palomares et al., 2012) .

Those trials were performed under controlled experimental conditions with low stress level and infectious pressure ensuring appropriate animal comfort and welfare. Stressors imposed on calves, such as abrupt weaning, lack of pre-conditioning, weather extremes, irregular vaccination, long transportation, comingling and excessive location and diet changes can compromise the immune J o u r n a l P r e -p r o o f function and the response to vaccination due to oxidative stress, affecting animal health and performance. Moreover, the current global pressure for reducing antibiotic use in food animal production creates the need for vaccination protocols that induce enhanced protection and limit disease transmission more efficiently.

Numerous studies have proven the effects of trace minerals such as selenium (Se), zinc (Zn), copper (Cu), and manganese (Mn) on immunity (Chirase et al., 1994; Percival, 1998; Underwood and Suttle, 1999) , health and growth performance of cattle (Spears and Kegley, 2002) .

The impact of these minerals on the immune function has been associated with their role in the structure and function of antioxidant enzymes (e.g. superoxide dismutase, glutathione peroxidase), nucleic acid replication and transcription, mitochondrial metabolic cascades, among others (Tomlinson et al., 2008; Haase and Rink, 2014) ; resulting in improvement of neutrophil migration and phagocytic function, lymphocyte proliferation and antibody production (Pina et al., 2002; Tomlinson et al., 2008; Arthington and Havenga, 2012; Haase and Rink, 2014; Bonaventura et al., 2015) . The use of trace mineral supplementation may become particularly important in highly stressed cattle, such as newly received feeder calves (Duff and Galyean, 2007) . Administration of injectable trace minerals (ITM) has shown beneficial effects on antibody production and cell mediated immune response to BRD vaccines in beef (Arthington and Havenga, 2012; Roberts et al., 2016) and dairy cattle (Palomares et al., 2016; Bittar et al., 2018a) . A recent study developed by our group demonstrated that the use of ITM concomitant with an MLV-BRD vaccine in dairy calves resulted in earlier and greater serum neutralizing antibody titers to BVDV1 and Mannheimia haemolytica, and more rapid and stronger mononuclear cell proliferation upon stimulation with BVDV1, BRSV and Pasteurella multocida than the control calves (Palomares et al., 2016; Bittar et al., 2018a) . After this study, there was a question as to whether the use of ITM could also favor J o u r n a l P r e -p r o o f the induction of a more rapid and improved immune response and protection shortly after vaccination in situations where a fast protection is required, such as that of newly received calves vaccinated at arrival and shortly exposed to BRD pathogens. Therefore, in the present study we hypothesized that administration of ITM at the time of MLV-BRD vaccination would benefit the immune response and protection in newly received BVDV-naïve beef calves experimentally challenged with BVDV five days after vaccination. The objective of this study was to determine if the use of injectable trace minerals (containing Se, Zn, Cu, and Mn) supplementation concurrent with a modified-live virus (MLV) vaccine is able to enhance the immune response and onset of protection against an experimental BVDV2 infection in newly received BVDV-naïve beef calves challenged 5 days after vaccination.

The study was done at the University of Georgia (UGA) Oconee Farm (Watkinsville-GA) from May through June 2016. The research protocol was approved by the University of Georgia, Institutional Animal Care and Use Committee (UGA-AUP# A2014 02-005-Y3 A8). This study was performed using 45 weaned Angus and Angus-crossbred calves (7 months old) purchased from a commercial ranch in Calhoun, GA. The calves were BVDV-naïve confirmed via standard virus neutralization test for serum neutralizing antibodies (SNA) titers against BVDV1 and 2, and ear notch biopsy for immunohistochemistry (BVDV antigen) done at the University of Georgia, Athens Veterinary Diagnostic Laboratory (Athens, GA). The calves and their dams were not vaccinated with BRD vaccines on the farm of origin before the beginning of the study in order to maintain the calves' BVDV-naïve status. In addition, the calves and their dams were kept in an J o u r n a l P r e -p r o o f isolation pasture away from the main herd from birth to weaning to avoid contact with MLV from vaccinated cattle. At the farm of origin, the calves grazed rye grass (Lolium hybridum) with free access to bermuda grass hay (Cynodon dactylon), and water ad libitum.

On day -7, calves were transported for approximately 8 hours from the farm of origin in Calhoun, GA to the Oconee Farm of the College of Veterinary Medicine at University of Georgia (UGA) at Watkinsville, GA. On the experimental farm, the calves grazed fescue grass (Festuca arundinacea) with free access to bermuda grass hay (Cynodon dactylon), and water ad libitum. In addition, calves were supplemented (2.5 Kgs per calf/day) of a commercial ration that contained trace minerals (Cattleman's Special Beef; Godfreys Warehouse; Madison-GA) offered in two meals. Additional oral mineral supplementation was not provided during this study.

On day -5, calves were randomly assigned to one of the three groups: VAC+ITM (n= 15): calves received 2 mL of a 5-way MLV vaccine containing BHV1, BVDV1 and 2, BRSV, PI3V The stock BVDV-2 strain 890 utilized in this trial was biologically cloned using successive passages as previously described (Bittar et al., 2018b) . This strain has been previously proven to successfully induce lymphopenia and neutrophilia with mild to moderate clinical disease in nonvaccinated calves (Walz et al., 2001; Bittar et al., 2018b) . Manassas, VA) as previously described (Bittar et al., 2018b) . The inocula remained frozen at -80°C until the day of challenge. One hour before challenge, the frozen inoculum was thawed.

Then, 5 mLs of the BVDV2 inoculum were aliquoted into individual 12 mL sterile syringes, transported to the farm held in ice until use. The challenge was done by intranasal aerosolization of 5 mL of inoculum (2.5 mL in each nostril) with a 10 cm long tip-fenestrated cannula coupled to a 12 mL syringe for each individual animal, as previously described (Bittar et al., 2018b) . After J o u r n a l P r e -p r o o f challenge all calves comingled in a 10-acre pasture with adequate shade, during the rest of the experimental period. A sample (5 mL) of the inoculum was transported on ice to the lab to determine the virus concentration (TCID50/mL) after challenges were finished.

Calves' health status comprising rectal temperature, hydration, attitude, eyes and nasal discharge and fecal consistency, was assessed using the University of Wisconsin's scoring system (http://www.vetmed.wisc.edu/dms/fapm/fapmtools/8calf/calf_health_scoring_chart.pdf). Clinical examination was performed on each calf on study days -6, -5, 0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18 and 21 relative to the day of BVDV challenge. However, rectal temperatures were measured only on study days -6, -5, 0, 3, 5, 6, 7, 8, 9, 11, 14 and 18 . Clinical signs were assessed for each variable (hydration status, nasal secretion, head-ears [attitude], feces, eyes, and cough) on a scale from 0 to 3, with 0 representing a lack of clinical signs and 3 representing severe clinical signs. The daily sum health score was the total sum of each individual clinical sign, and was calculated by adding all individual scores of the six clinical variables, as previously described (Bittar et al., 2018b) . Three experienced veterinarians, who were not aware of calves' treatment allocation, assessed clinical signs and health scores.

Blood samples were collected from the jugular vein using an 18 gauge x 2.5-cm single sample needle (Vacuette®; Nipro Medical Industries Ltd., Gunma, Japan) into vacuum tubes (Vacutainer®, BD Diagnosis, Franklin Lakes, NJ) with and without anticoagulant to obtain whole blood and serum, respectively. Blood samples were collected on study days -14, -6, -5, 0, 3, 5, 6, J o u r n a l P r e -p r o o f 7, 8, 9, 11, 14, 18, 21 and 28 . Blood collection was done into four individual 8.5 mL glass tubes for buffy coat separation (BD Vacutainer ACD Solution A REF364606®; BD Diagnosis, Franklin Lakes, NJ), and into one 2 mL polypropylene tube for leukocyte and platelet count (BD Vacutainer K2 EDTA 3.6mg REF367841®; BD Diagnosis, Franklin Lakes, NJ). In addition, blood samples were collected into two individual 10 mL glass tubes without anticoagulant (BD Vacutainer Serum®; BD Diagnosis, Franklin Lakes, NJ) for serum mineral concentration, and serum neutralizing antibody (SNA) titers to BVDV1 and 2.

The blood samples containing ACD Solution A were processed for buffy coat isolation as previously described (Harpin et al., 1999) and freshly used for staining for flow cytometry analysis or stored at -80 o C for further real time quantitative reverse transcription polymerase chain reaction (qRT-PCR) for BVDV1 and 2 nucleic acid detection. Clotted blood samples were centrifuged (900x g for 15min) for serum separation, and serum samples were stored at -80 o C for for determination of SNA titers against BVDV1 and 2.

Nasal swab samples were collected from each calf for BVDV nucleic acid detection using qRT-PCR on study days 0, 5 and 7. An individual cotton swab was inserted in each nostril scraping the nasal mucosa, and placed in a tube containing 3 mL of PBS with penicillin-streptomycin and amphotericin, and then transported to the laboratory for processing as previously described (Bittar et al., 2018b) . Samples were mixed using a vortex; then swabs were removed and the solution was filtered and stored at -80 o C for subsequent qRT-PCR.

Trace mineral status in liver biopsy samples (15 mg of liver tissue) was assessed from each calf on days -14, and 21 relative to the day of vaccination. Liver biopsies were collected using sterile surgical tru-cut semi-automatic biopsy needles (14 g and four inches long) with the assistance of ultrasonography (Ibex®Lite, E.I. Imaging, Loveland, CO) for liver visualization and 

Blood samples for serum neutralizing antibodies (SNA) titers against BVDV1 and 2 were collected on days -14, -5, 0, 7, 14, 21 and 28. Serum neutralizing antibody titers against BVDV1 and 2 were determined at the University of Georgia Athens Veterinary Diagnostic Laboratory (Athens, GA) via a standard virus neutralization protocol as previously described (Bittar et al., 2018b) . In summary, after heat inactivation of serum samples (56 o C for 30 min), serum samples were serially diluted with DMEM into a 2-fold dilution series, beginning at 1:2 in 96-well cell culture plates. An equal volume of the appropriate cytopathic BVDV1 and 2 was added to each well (25 μL of DMEM with approximately 100 TCID50 of the respective viruses strain) making the starting serum dilution of 1:4. After incubation (5% CO2 at 37 o C for 1 h) MDBK cell suspension was added to each well (150 μL suspension with approximately 1.8 x 10 4 cells in DMEM containing 10% fetal calf serum [FCS] ).

The cell monolayer was examined with an inverted microscope for signs of virus-specific cytopathic effects after plates were incubated for 4 days (5% CO2 at 37 o C). The SNA titer for each sample was reported as the reciprocal of the highest dilution of serum that completely inhibited virus-induced cytopathic effects.

J o u r n a l P r e -p r o o f Blood samples for total white blood cells, lymphocyte, granulocyte, monocyte and platelet counts were collected on days -14, -6, -5, 0, 3, 5, 6, 7, 8, 9, 11, 14 and 18 . Tubes with uncoagulated blood samples containing EDTA were kept cooled in ice, and posteriorly transported to the Department of Veterinary Pathology of the University of Georgia (UGA) in Athens, GA for complete blood count (CBC). Blood samples were then kept in room temperature on an orbital shaker to be stirred for 10 minutes before analysis. Total leukocyte, platelet and differential leukocyte counts for each sample were determined by use of an automatic cell counter (HESKA® CBC-Diff, Vet Hematology System, Des Moines, IA).

Blood samples for T-cell phenotyping (CD4, CD8, and WC1) including CD25 expression were collected on days -6, 0, 3, 7, 14 and 18. For each blood sample a buffy coat was prepared.

The leukocytes were assessed for cell viability (exclusion in 0.04% trypan blue) and cell number using a hemocytometer chamber. The cells were suspended to a concentration of approximately 6x10 6 cells per mL. The samples all had 85% viability or greater. Each sample was diluted in 3 mL PBS-1X in individual pre-labeled tubes (12x75 mm polystyrene. Falcon, BD Biosciences, San José, CA). The cells were washed twice by centrifugation (300 x g for 5 minutes). The supernatant was discarded after each wash. The cells were suspended in 1.5 mL of FACS buffer (PBS with 0.5% bovine serum albumin, and 0.1% sodium azide) and mixed uniformly by vortexing. For staining, 100 µL of cells suspension (approximately 3x10 6 cells) were added per well to a 96-well round bottom microtiter plate. Plates were centrifuged (300 x g for 5 minutes) and snapped sharply to remove the supernatant. Each plate was vortexed with lid on to suspend the cells in the residual volume. At this point, 20 µL of each antibody tested (at the minimum saturating concentration) J o u r n a l P r e -p r o o f was added to the desired wells, and wells that were dual stained (combination of CD25 with either CD4, CD8 or WC1). The primary antibodies were mouse anti-bovine CD4 isotype IgG2a antibody at a 1:5 dilution (clone CC8, MCA1653F, BioRad, Hercules, CA), mouse anti-bovine CD8 isotype IgG2a antibody at a 1:5 dilution (clone CC63, MCA837F, BioRad, Hercules, CA), mouse antibovine WC1 (gamma-delta T cell) isotype IgG2a antibody at a 1:5 dilution (clone CC15, MCA838F, BioRad, Hercules, CA), and mouse anti-bovine CD25 isotype IgG1 antibody at a 1:7 dilution (clone IL-A111, MCA2430PE). FACS buffer was added to wells to function as an unstained control. A combination of CD25 and each of the other T-cell (CD4, CD8 and WC1) antibodies were used to stain the cells. Plates were incubated (4 o C for 45 minutes). Following staining, the plates were washed three times with FACS buffer (300 x g for 5 minutes). At the end of each wash, the plates were snapped sharply to remove the supernatant. Each plate was vortexed with lid on to suspend the cells in the residual volume. After the last wash, the supernatant was discarded and the cells were suspended in FACS fix (4% formalin in FACS buffer). Each well received 100 µL of FACS fix. The plates were incubated overnight (18-20 hours) at 4 o C. Well contents were transferred into a pre-labeled 1.5 mL microcentrifuge tubes (MCT) containing 300 µL of FACS buffer. After dilution of FACS buffer, samples were stored for flow cytometry analysis at 4ºC. All samples were assessed within one week of fixation. Flow cytometry was done using a BD Accuri C6 first generation cytometer and C-flow plus software (BD Biosciences, Franklin Lakes, NJ). Samples were gated using FALS and 90LS two parameter histograms to identify the lymphocyte, monocyte and granulocyte cells in the sample based on previous validation with highly enriched populations of each. Compensation to minimize cross talk between FL1 and FL2 signal was established using single color samples at minimum saturating concentration to eliminate green in orange and orange in green color bleed. The positive and J o u r n a l P r e -p r o o f negative windows for FL1 and FL2 single color analysis, and FL1-FL2 dual parameter histograms were established in preliminary trials using staphylococcal enterotoxin B stimulated buffy coat cells under the same staining conditions and set in a template for flow collection. Approximately 10,000 events were recorded in the lymphocyte gate for each sample. Following data collection, the lymphocyte gate was confirmed using the list mode data for each sample to assure that the same population was measured for each sample across the total experiment. The C-flow plus software was used to generate values for percent positive cells for each marker, and for CD25 positive cells within each marker. In addition, values for the mean fluorescent intensity were generated from the analysis gates for each marker and for the CD25 population within each marker for all samples in the trial.

Buffy coat and nasal swab samples that had been stored at -80 o C were thawed at room temperature for BVDV nucleic acid detection. Total RNA was extracted from buffy coats and nasal swab solutions using RNeasy Mini Kit (QIAGEN, Germantown, MD). Total RNA samples were submitted to the Athens Veterinary Diagnostic Laboratory where a BVDV1 and 2 multiplex qRT-PCR was performed as previously described (Letellier and Kerkhofs, 2003) . Total RNA samples were reverse transcribed in the presence of hexanucleotides. One microliter of the resulting cDNAs were used for real-time PCR analysis (Letellier and Kerkhofs, 2003) . Based on conserved regions of the 5' UTR of BVDV1 and 2, the primer pair F2: 5' 1D ).

Rectal temperatures increased in the UNVAC group after BVDV2 challenge, peaking by days 7 and 8 (Fig. 2) . Unvaccinated calves had significantly higher rectal temperature than both vaccinated groups from days 5 to 9 after BVDV challenge (P< 0.05). There was no difference in rectal temperature between vaccinated groups during the experimental period. Sum daily health scores increased on days 3, 7, 8 and 9 post BVDV challenge in the UNVAC group (Fig. 3 Mean total leukocytes count significantly decreased in the UNVAC group from day 0 to day 5 (approx. 66%. Fig. 4A ) and remained low until day 11. These values were significantly lower J o u r n a l P r e -p r o o f than those in the vaccinated groups (P< 0.05). Vaccinated groups (treated with ITM or not) had similar mean leukocytes count along the study. Mean lymphocyte, granulocyte and monocyte counts significantly decreased in the UNVAC group between days 3 and 7 after BVDV challenge (P< 0.05; Fig. 4B , 4C and 4D), which was statistically different from vaccinated groups on the same days. Calves in both vaccinated groups had a slight decrease in lymphocyte, granulocyte and monocyte counts after vaccination and again on days 5 and 6 after BVDV challenge, with no significant difference between groups (Fig. 4B, 4C and 4D ). Platelets count significantly declined after BVDV challenge in the UNVAC calves until days 8 and 9 (Fig. 4E) . Differently, platelet counts increased in the VAC+ITM group after day 3, while they remained unaffected in the VAC+SAL group. Vaccinated calves that were treated with ITM had significantly higher platelet count compared to VAC+SAL (days 5, 6, and 9; P< 0.05) and UNVAC calves (days 3, 5, 6, 7, 8, 9, and 11; P< 0.05. Fig. 4E ).

Serum neutralizing-antibodies (SNA) titers against BVDV1 and BVDV2 were low (<1:8) before challenge (on days -14, -5, and 0) in all groups ( Fig. 5A and 5B ). SNA titers against BVDV1 dramatically increased (>4 log2) within two weeks after BVDV challenge in both vaccinated groups (Fig. 5A ). Calves in VAC+ITM had higher BVDV1 SNA titers on day 28 compared with the VAC+SAL group (P< 0.05). Unvaccinated calves had lower SNA titers against BVDV1 after challenge than both vaccinated groups (P< 0.05). There was a moderate increase (approx. 2.5 log2)

in BVDV1 SNA titers only on day 28 post challenge in the UNVAC group (Fig. 5A) . Moreover, SNA titers against BVDV2 dramatically increased (> 5 log2) in VAC+ITM and VAC+SAL groups by days 21 and 28, respectively (Fig. 5B) . Calves in the VAC+ITM group had higher BVDV2

SNA titers compared to the other groups on days 21 and 28 (P< 0.05). Calves in the UNVAC group J o u r n a l P r e -p r o o f had also a rise of BVDV2 SNA titers (approx. 3.5 log2) by day 28 after BVDV challenge, which were significantly lower than those in VAC+ITM and VAC+SAL groups (P< 0.05). 

In the current study, vaccination provided rapid protection from experimental infection with BVDV2 in newly-received beef calves. The efficacy of vaccination was demonstrated by lesser health scores (associated to improved health status according to the evaluation system used with low or high virulence BVDV at 3, 5 or 7 days after primary vaccination (Brock et al., 2007; Palomares et al., 2012) . These studies demonstrated rapid protection against BVDV acute infection when vaccination was given 5 or 7 days before challenge. However, a high percentage of calves J o u r n a l P r e -p r o o f challenged 3 days after vaccination shed BVDV. At least in the context of BVDV prevention, our results and those of previous studies (Brock et al., 2007; Palomares et al., 2012) , showing adequate immune response and rapid protection elicited by vaccination, provide evidence that may support strategic vaccination at the time of cattle arrival, reducing quarantine periods and intervals between vaccination and commingling with other cattle, which might facilitate farm management practices.

Further, this study tested the strategy of using ITM concurrent with vaccination in an attempt to improve the protective immune response to BVDV in newly received beef calves challenged few days after vaccination.

Severe BVDV-induced leukopenia and thrombocytopenia were observed in the causing mild to fatal bronchitis and pneumonia (Brogden and Guthmiller, 2002) . Reduction in platelet number is a common hematological finding in infections with some BVDV2 strains and has been associated with a hemorrhagic syndrome (Rebhun et al., 1989) . Administration of ITM were observed in our previous trial evaluating the long-term protection elicited by MLV vaccination and ITM supplementation against BVDV2 infection in dairy calves (Bittar et al., 2018b) .

The commercial vaccine used in this study was able to reduce viremia and viral shedding after BVDV infection, as represented by the lower number of BVDV2 positive buffy coat and nasal swab samples in both vaccinated groups on days 5 and 7 after experimental BVDV2 challenge compared with the unvaccinated group, which is in agreement with previous studies using different BVDV strains (Brock et al., 2007; Palomares et al., 2012) . However, supplementation with ITM showed no additional beneficial effects reducing BVDV detection in peripheral leukocytes and nasal swab samples.

The humoral immune response post BVDV challenge was greater in both vaccinated groups compared to the unvaccinated calves. Calves treated with ITM had greater SNA titers to BVDV1 and BVDV2 compared to the other groups. Previous field studies have shown association between higher SNA titers and health performance in calves at feedlot receiving (Fulton et al., 2002; Campbell, 2004) . Production of neutralizing antibodies is one of the major features of the It would have been interesting to include an 'ITM alone group' in the experimental design to test the effects of ITM administration on the immune response after challenge with BVDV2, as ITM administration was suggested to improve the general health status of young calves (Teixeira et al., 2014) . However, administration of ITM is not intended to induce specific protective immunity against respiratory pathogens by itself or replace vaccination.

In summary, MLV-BRD vaccination concurrent with ITM or not, induced a rapid protection against BVDV infection. In addition, administration of ITM at the time of vaccination was associated with increased humoral immune response to BVDV1 and 2, enhanced health status, appeared to mitigate the decrease in the percentage of peripheral blood circulating CD4 + and CD8 + T cells, and reduced their activation in beef calves challenged with BVDV2 five days after vaccination. Moreover, administration of ITM at the time of vaccination was associated with significantly increased platelet counts after BVDV challenge. These results support the strategic use of ITM concurrently with vaccination protocols, especially when a rapid immune response and protection is needed in newly received beef calves.

The authors of this article, declare that there are no conflicts of interest.

Hoek, A., Rutten, V.P., Kool, J., Arkesteijn, G.J., Bouwstra, R.J., Van Rhijn, I., and Koets, A.P., 2009 . Subpopulations of bovine WC1 + γδ T cells rather than CD4 + CD25 high Foxp3 + T cells act as immune regulatory cells ex vivo. Vet. Res. 40, 6-20.

Howard Errors bars represent the SEM. x, y, z Significant difference between groups by each study day (P< 0.05). at study day -5 and were individually challenged with ncp BVDV2 (strain 890) five days later (day 0). Errors bars represent the SEM.

x, y, z Significant difference between groups by each study day (P< 0.05). 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 6.7% (1) 0 (0) 33.3% (5)* 13.3% (2) 13.3% (2) 33.3% (5) 7 0 (0) 6.7% (1) 73.4% (11)* 13.3% (2) 6.7% (1) 20% (3) Cumulative 1 6.7% (1) 6.7% (1) 93.3% (14)* 26.7% (4) 13.3% (2) 46.7% (7) 1 Represents the total number of calves with at least one positive BVDV PCR result in all days out of 15 calves in each group (if a calf tested positive in more than one day, it was counted only once). 

Cellular and molecular immunology

Effect of injectable trace minerals on the humoral immune response to multivalent vaccine administration in beef calves

Effects of injectable trace minerals on the immune response to Mannheimia haemolytica and Pasteurella multocida following vaccination of dairy calves with a commercial attenuated-live bacterin vaccine

Effects of injectable trace minerals administered concurrently with a modified live virus vaccine on long-term protection against bovine viral diarrhea virus acute infection in dairy calves

Zinc and its role in immunity and inflammation

Strategies for the control and prevention of bovine viral diarrhea virus

Polymicrobial Diseases

Effect of bovine viral diarrhea virus in the feedlot

The immune response to bovine viral diarrhea virus: a constantly changing picture

Recovery rate and plasma zinc and copper concentrations of steer calves fed organic and inorganic zinc and manganese sources with or without injectable copper and challenged with infectious bovine rhinotracheitis virus

Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge

Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle

Bovine viral diarrhea viral infections in feeder calves with respiratory disease: interactions with Pasteurella spp., parainfluenza-3 virus, and bovine respiratory syncytial virus

Evaluation of health status of calves and the impact on feedlot performance: assessment of a retained ownership program for postweaning calves

Economic impact associated to respiratory disease in beef cattle

Bovine γδ T cells are a major regulatory T cell subset

Multiple impacts of zinc on immune function

Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhoea virus major glycoprotein E2

The Use of Blood Analysis to Evaluate Trace Mineral Status in Ruminant Livestock

Thrombocytopenia associated with acute bovine virus diarrhea infection in cattle

Differential cytokine responses of CD4 + and CD8 + t cells in response to bovine viral diarrhoea virus in cattle

Effect of injectable trace mineral administration on health, performance and vaccine response of newly received beef cattle

Effect of supplemental trace minerals from injection on health and performance of highly stressed, newly received beef calves. The Prof

Mixed viral etiology of a shipping fever epizootic in cattle

Effect of zinc source (zinc oxide vs zinc proteinate) and level on performance, carcass characteristics, and immune response of growing and finishing steers

The epidemiology of bovine respiratory disease: What is the evidence for predisposing factors? The Canadian Vet

Effect of an injectable trace mineral supplement containing selenium, copper, zinc, and manganese on immunity, health, and growth of dairy calves

Role of trace minerals in the immune system

The mineral nutrition of livestock

Beef 2007-08. Part IV: reference of beef bow-calf management practices in the United States

Least square means (LSM) and standard error of the mean (SEM) for percentage of CD4 + (A)

CD8 + CD25 + (E), and WC1 + CD25 + (F) T-cell phenotype in peripheral blood circulation of beef calves treated (VAC+ITM) or not (VAC+SAL) with injectable trace minerals (ITM) concurrently with MLV-BRD vaccination

Errors bars represent the SEM. x, y Significant difference between groups on each study day (P< 0.05). † Significant difference relative to day 0 for VAC+ITM (P< 0.05). ‡ Significant difference relative to day 0 for the VAC+SAL group